← Back to Compounds
injectableanabolic

Drostanolone Enanthate

Masteron EMasteron EnanthateMast EDrost E
62
Anabolic Ratio
25
Androgenic Ratio
7d
Half-Life

Long-ester version of Drostanolone (Masteron). A DHT derivative with anti-estrogenic properties, commonly used during contest prep for a hard, dry cosmetic look. Longer half-life than Masteron Propionate allows less frequent injections.

Mechanism of Action

DHT derivative that binds androgen receptors and exhibits anti-estrogenic activity. Does not aromatize into estrogen. May inhibit aromatase to some degree, reducing estrogen conversion from other aromatizing steroids in the stack. Primarily valued for its cosmetic muscle-hardening effect and mild strength gains. Targeted action on contractile tissue without water retention.

Drostanolone Enanthate molecule
Molecular structure

Typical Dosing

200 mg
low / week
400 mg
moderate / week
600 mg
high / week

⚠ Warning Flags

  • Significant hair loss risk in those predisposed to androgenic alopecia
  • Lipid suppression — monitor HDL/LDL
  • Limited mass-building capacity — primarily a cosmetic/contest prep compound
  • No aromatization = requires a testosterone base for estrogen support

Effect Profile

Muscle Protein Synthesis
4Low
Nitrogen Retention
4Low
Strength Gains
5Moderate
Red Blood Cell Production
2Minimal
Fat Loss
6Moderate
Glycogen Storage
3Low
Recovery Speed
4Low
Collagen Synthesis
3Low

Side Effect Profile

Hormonal Suppression
5Moderate
Estrogenic Effects
1Minimal
Androgenic Effects
5Moderate
Cardiovascular Strain
4Low
Liver Stress
1Minimal
Insulin Resistance
1Minimal
Mood Changes
2Minimal
Prostate Risk
4Low

Research Studies

Drostanolone, an aromatase inhibitor, in the treatment of breast cancer in postmenopausal women

Chaudry MA et al. · 1985

PubMed

Demonstrated Drostanolone's anti-estrogenic effect in clinical use for estrogen-receptor-positive breast cancer.

Anabolic steroids: an overview

Ganesan K et al. · 2021

PubMed

Reviews the pharmacology of androgens including Drostanolone's hormonal modulation and tissue selectivity.

Structural characteristics of anabolic androgenic steroids contributing to binding to the androgen receptor

Fragkaki AG et al. · 2009

PubMed

Confirms DHT derivatives like Drostanolone exhibit targeted androgen receptor binding profiles.